{"id":"W4387160441","doi":"10.1016/s2666-5247(23)00177-5","title":"Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland","year":2023,"lang":"en","type":"article","venue":"The Lancet Microbe","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Medical Research Council; Shionogi; University of Oxford; Department of Health and Social Care; Moderna; Coalition for Epidemic Preparedness Innovations; Seqirus; AstraZeneca; National Institute for Health and Care Research; Bill and Melinda Gates Foundation","keywords":"Immunogenicity; Medicine; Randomized controlled trial; Cohort; Internal medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Antibody; Immunology; Disease; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004706177,0.0004353379,0.001230204,0.0003318351,0.0004331843,0.0001522957,0.0005172272,0.0001395888,0.000006393306],"category_scores_gemma":[0.0008696051,0.0002777999,0.0001404578,0.0008965321,0.0001229202,0.0001276664,0.0005273661,0.0005494182,0.000006449957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001410735,"about_ca_system_score_gemma":0.0004234633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005623061,"about_ca_topic_score_gemma":0.002177919,"domain_scores_codex":[0.996732,0.0004494342,0.0008383141,0.0007222718,0.0003932237,0.0008647378],"domain_scores_gemma":[0.996824,0.001613491,0.0002552697,0.0009511869,0.0001876929,0.0001683548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6139594,0.001595086,0.2146042,0.00228704,0.001166522,0.0005234084,0.0663429,0.0000154428,0.0924226,0.00006017206,0.001777528,0.00524575],"study_design_scores_gemma":[0.8444752,0.003450917,0.1125075,0.000848412,0.001071856,0.0007292808,0.01610901,0.002733534,0.008094128,0.0001446442,0.008978423,0.0008570831],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823557,0.002486605,0.0001715882,0.003544476,0.00008093299,0.01106082,0.0001643965,0.00007807099,0.00005741216],"genre_scores_gemma":[0.9847625,0.0005710093,0.00009355482,0.01385684,0.0001378723,0.0004840079,0.00003038155,0.00004748442,0.00001637414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2305158,"threshold_uncertainty_score":0.9999674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05338598424773385,"score_gpt":0.3800198132191175,"score_spread":0.3266338289713837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}